Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Form 8.3 - UK Commercial Property REIT
-
Form 8.3 - Urban Logistics REIT plc
-
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity
-
Camfil APC Unveils Essential Guide to Metal Dust Collection and Safety Regulations
-
C.K. McWhorter's Visionary Cartoon Series Marks a New Era in Luxury and Financial Education for Minority Youth
-
C.K. McWhorter's Visionary Cartoon Series Marks a New Era in Luxury and Financial Education for Minority Youth
-
Diana Shipping Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2023; Declares Cash Dividend of $0.075 Per Share for the Fourth Quarter 2023; Announces the Sale of a C
-
Alliance Trust PLC - Net Asset Value
-
FEMSA Forward - Focused Leadership in Retail, Beverages & Digital
-
FEMSA Forward - Focused Leadership in Retail, Beverages & Digital
-
Six Years Strong: Founder of Revitalist Kathryn Walker’s Continuous Leadership in Revolutionizing Mental Health Care
-
FEMSA Announces Fourth Quarter and Full Year 2023 Results
-
Collective Audience CEO and Chairman Discuss the Rapidly Evolving AdTech Industry in Interview by Veteran Broadcaster, Jane King, at Nasdaq MarketSite
-
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
-
BioElectronics Corporation Announces the Publication of Pilot Study Results
-
Wintrust Financial Corporation and LPL Financial Announce Strategic Relationship
-
Phunware Announces Reverse Stock Split
-
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
-
Form 8.3 - Irish Residential Properties REIT plc
-
AgEagle Announces Sale of Altum-PT Multispectral Cameras to Department of Defense Customer through ADS, Inc.
-
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
-
QCR Holdings, Inc. Announces a Cash Dividend of $0.06 Per Share
-
Dominion Lending Centres Inc. Announces New President of Mortgage Architects
-
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
-
Jasco Announced as Finalist for Best of IBS Awards
-
Commercial National Financial Corporation Announces Quarterly Dividend
-
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
-
CGS BlueCherry® and TradeLink Technologies to Partner at Bharat Tex 2024 to Showcase end-to-end Factory RFID Solution
-
Unlocking Passive Income with DefiQuant's Automated Trading Bot
-
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
-
Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
-
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
Worksport Ltd. Announces New Distribution Partnership with Dix Performance North to Expand Presence Across Canada
-
Comscore to Announce Fourth Quarter 2023 Financial Results
-
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
-
Alkami to Present at Citizens JMP Technology Conference
-
InspireSemi Announces Partial Conversion of Debentures
-
Textainer Announces Shareholder Approval of Its Pending Acquisition by Stonepeak and Receipt of Required Antitrust Approvals
-
Man Group PLC : Form 8.3 - Custodian Property Income REIT Plc
-
Man Group PLC : Form 8.3 - UK Commercial Property REIT Limited
-
Man Group PLC : Form 8.3 - Tritax Big Box Reit Plc
-
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
-
Brixton Metals Receives Typhoon™ Results and Additional Assays from the Hog Heaven Project, Montana
-
Man Group PLC : Form 8.3 - Redrow plc
-
Man Group PLC : Form 8.3 - Barratt Developments plc
-
Invesco Ltd: Form 8.3 - LXI REIT PLC - Updated OPD to include additional dealings
-
Invesco Ltd: Form 8.3 - LondonMetric Property PLC - Updated OPD to include additional dealings
-
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
-
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
-
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
